Tesamorelin – Technical Brief (For Research-Use-Only)
1. Identity
Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), designed to stimulate the release of growth hormone (GH) from the pituitary gland. It has been primarily studied for its role in reducing visceral fat and improving metabolic health.
2. Mechanism of Action
Tesamorelin works by:
- Binding to GHRH receptors: Stimulates the pituitary gland to release GH.
- Mimicking natural GH secretion: Induces a pulsatile release pattern.
- Reducing visceral adipose tissue (VAT): Helps manage fat accumulation, particularly in HIV-associated lipodystrophy.
3. Uses
Tesamorelin is primarily researched for:
- HIV-associated lipodystrophy: Approved for reducing VAT in affected patients.
- Metabolic health: Investigated for its role in improving insulin sensitivity and lipid profiles.
- Potential cognitive benefits: Some studies suggest neuroprotective effects.
4. Dosage
Standard dosing protocols include:
- Daily injection: 1mg (1000mcg) subcutaneously.
- Reconstitution: A 6mg vial is typically mixed with 2mL of bacteriostatic water.
- Administration: Best taken on an empty stomach, as fats and carbohydrates may reduce efficacy.
5. Safety Profile
- Common side effects: Mild irritation at the injection site, occasional headaches.
- Precautions: Not recommended for individuals with active malignancies.
- Long-term effects: Generally well-tolerated, but ongoing studies continue to assess broader applications.
6. Storage Guidelines
- Before mixing: Store the lyophilized powder in a refrigerator (2–8°C / 36–46°F), protected from light.
- After mixing: Keep refrigerated and use within 30–45 days.
- Room temperature storage: Can be kept at up to 30°C (86°F) for a maximum of 21 days, but should not be returned to refrigeration afterward.
- Do not freeze: Freezing reconstituted vials can degrade the peptide’s integrity.
7. Legality in the UK
Tesamorelin is not approved for general medical use in the UK but is available for research purposes. It is primarily studied for HIV-associated lipodystrophy, but its broader applications remain under investigation. Regulatory bodies such as the MHRA (Medicines and Healthcare products Regulatory Agency) have not authorized it for widespread therapeutic use.
